Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (241,283)	$ (293,586)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	8,790	8,248
Non-cash operating lease cost	2,802	3,069
Non-cash interest expense and amortization of debt issuance costs	10,440	17,554
Acquired in-process research and development	39,765	75,301
Stock-based compensation	13,312	8,978
Loss on debt extinguishment	51,939
(Gain) Loss on derivative liabilities	(5,900)	35,792
Loss on equity method investments	5,821	3,902
Deferred tax provision	(1,989)	(782)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(313)	(7,727)
Accrued payroll	2,016	4,429
Prepaid expenses, deposits and other assets	4,588	(3,393)
Accounts payable	(8,556)	8,782
Accrued expenses and other liabilities	1,544	3,137
Deferred revenue	(385)	(581)
Other	(1,258)	(97)
Net cash used for operating activities	(118,667)	(136,974)
Investing activities
Purchases of property and equipment	(3,840)	(9,582)
Purchase of assets related to Semnur, net of cash acquired		(17,040)
Payments related to license agreements	(22,325)
Other acquisitions and investments	(2,344)	(1,162)
Net cash used for investing activities	(28,509)	(27,784)
Financing activities
Proceeds from short-term debt, net of issuance costs	7,815	18,858
Proceeds from exercise of stock options and warrants	97,810	289
Repayments of debt and other obligations	(132,819)	(2,441)
Net cash provided by (used for) financing activities	185,815	40,975
Net change in cash, cash equivalents and restricted cash	38,639	(123,783)
Net effect of exchange rate changes on cash	768	(156)
Cash, cash equivalents and restricted cash at beginning of period	80,769	213,330
Cash, cash equivalents and restricted cash at end of period	120,176	89,391
Cash paid during the period for:
Interest	3,148	10,046
Supplemental disclosures of non-cash investing and financing activities:
Semnur acquisition costs incurred but not paid		601
Other acquisitions, license agreements and investments paid in equity	9,544
Property and equipment costs incurred but not paid	1,524	1,408
Reconciliation of cash, cash equivalents and restricted cash within the Company’s consolidated balance sheets:
Cash and cash equivalents	75,176	34,649
Restricted cash	45,000	54,742
Cash, cash equivalents, and restricted cash	120,176	89,391
Semnur
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity		54,591
SmartPharm
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity	19,421
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 213,009	$ 24,269